AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01612247
Drug: Cyclophosphamide and Methotrexate and Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
Trial: NCT02034162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
Trial: NCT02660762
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
Trial: NCT01240538
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01289132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching tablets, orally, once daily for up to 12 weeks.
Trial: NCT03436303
Drug: CEE 0.625 mg/MP 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
Trial: NCT00008281
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00008281
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00008281
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02209844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02479997
Drug: Radioisotope
RxNorm normalized name: Radioisotope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
Trial: NCT01229774
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
Trial: NCT01229774
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
Trial: NCT00608725
Drug: Intrinsic Heart Rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Trial: NCT01508637
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
Trial: NCT00582725
Drug: R-CHOP+GM-CSF
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: addition of GM-CSF
Trial: NCT02828397
Drug: REGN2222
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02503826
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose
Trial: NCT02503826
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: moderate dose
Trial: NCT02503826
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high dose
Trial: NCT03617068
Drug: Cocos Nucifera Whole
RxNorm normalized name: COCOS NUCIFERA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance
Trial: NCT03617068
Drug: Cocos Nucifera Whole
RxNorm normalized name: COCOS NUCIFERA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For dermatopharmacokinetic evaluation using tape/ skin stripping
Trial: NCT01350232
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
Trial: NCT02825186
Drug: Loteprendol etabonate 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid eye drops used after strabismus surgery.
Trial: NCT04429282
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
Trial: NCT04429282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01625936
Drug: CRLX101 (Cerulean)
RxNorm normalized name: SAMBUCUS NIGRA SUBSP. CERULEA FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRLX101 is an innovative tumor-targeting nanopharmaceutical.
Trial: NCT01667926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04853901
Drug: Standard of care_1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
Trial: NCT04853901
Drug: Standard of care_2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 1-2mg/kg for 5-7 days
Trial: NCT00840996
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
Trial: NCT03518528
Drug: Estradiol 2 MG
RxNorm normalized name: estradiol 2 MG
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
Trial: NCT03518528
Drug: Estradiol 100 µg
RxNorm normalized name: estradiol 100 MG
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
Trial: NCT02034019
Drug: Punctum Plug
RxNorm normalized name: Hippeastrum puniceum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01352143
Drug: Recombinant activated factor VII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
Trial: NCT00944229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of placebo every 24 hours
Trial: NCT00162617
Drug: Red blood cell transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01296009
Drug: Traditional Chinese medicine(Zhuyun Recipe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
Trial: NCT02383992
Drug: 3% H2O2 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02383992
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00867100
Drug: 700 mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Trial: NCT00867100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Trial: NCT02484378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT02906020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule Route of administration: oral
Trial: NCT02701062
Drug: Anticoagulation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
Trial: NCT01973140
Drug: Hypertonic saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
Trial: NCT01598103
Drug: SAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
Trial: NCT01598103
Drug: Placebo to SAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
Trial: NCT04360122
Drug: Levamisole and Isoprinosine
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
Trial: NCT04434248
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
Trial: NCT00698282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00216047
Drug: PTK787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTK787 daily
Trial: NCT02036437
Drug: Misotac® Sigma Pharmaceutical Industries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
Trial: NCT02036437
Drug: Dinoprostone 3 mg
RxNorm normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
Trial: NCT02579824
Drug: DS-3032b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
Trial: NCT01150045
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive celecoxib 400 mg administered by mouth, once daily.
Trial: NCT01150045
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive 400 mg/m\^2 intravenous over two hours.
Trial: NCT00884650
Drug: oral analgesic
RxNorm normalized name: Oral Analgesic Paste Maximum Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per clinical standard of care
Trial: NCT00884650
Drug: intravenous analgesic per pump
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per clinical standard of care
Trial: NCT02054676
Drug: Medications.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days.
Trial: NCT00435851
Drug: Thyrogen, thyroid hormone withdrawal, iode 131
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00543062
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato placebo (0 mg)
Trial: NCT02791490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, once daily at approximately the same time each day
Trial: NCT00543062
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (identical to 400 mg moxifloxacin)
Trial: NCT01620970
Drug: PF03446962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
Trial: NCT00021047
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02075619
Drug: Amlodipine+Rosuvastatin
RxNorm normalized name: rosuvastatin and amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
Trial: NCT02075619
Drug: GSK3074477 FDC - 1
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
Trial: NCT02075619
Drug: GSK3074477 FDC - 2
RxNorm normalized name: DYE FDC BLUE #2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
Trial: NCT01923896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose powder
Trial: NCT03069144
Drug: HAT1 topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Trial: NCT00610909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00620269
Drug: Induction or consolidation IP chemotherapy
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
Trial: NCT00867737
Drug: Advair HFA MDI 115/21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two puffs from MDI twice daily for 4 weeks
Trial: NCT00867737
Drug: Symbicort 160/4.5 pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks
Trial: NCT00865852
Drug: GLUCOPHAGE® XR 750 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Trial: NCT04451811
Drug: OPL-002
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spray dried dispersion and tablet formulation
Trial: NCT01519778
Drug: TR701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 200 mg once daily
Trial: NCT01006616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to navarixin capsules
Trial: NCT01006616
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
Trial: NCT03672175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-217 matched placebo hard gelatin capsules.
Trial: NCT01322009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
Trial: NCT00905034
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 by vein on days 1 and 15.
Trial: NCT03251612
Drug: Based on sensitivity analysis
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin
Trial: NCT03856047
Drug: NNC0174-0833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
Trial: NCT00927498
Drug: conventional chemotherapy (AraC + Daunorubicin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
Trial: NCT00927498
Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.
Trial: NCT04211389
Drug: ARQ-151 0.3% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 0.3% cream
Trial: NCT04211389
Drug: ARQ-151 vehicle cream
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 vehicle cream
Trial: NCT00474929
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
Trial: NCT03938064
Drug: Prontogest 400 mg vaginal pessaries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: natural progesterone in the form of vaginal suppositories 400 mg
Trial: NCT01348152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
Trial: NCT02280057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills per day in six months; pills look like metformin pills
Trial: NCT00603083
Drug: Ropivacaine, Ketorolac and Adrenalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
Trial: NCT02757521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Trial: NCT01365533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one tablet once daily, orally
Trial: NCT02760758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active ingredients